Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Total 13F shares
-
37,677,821
-
Share change
-
+37,677,821
-
Total reported value
-
$2,254,528,000
-
Price per share
-
$60.25
-
Number of holders
-
69
-
Value change
-
+$2,254,527,999
-
Number of buys
-
69
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q2 2021
As of 30 Jun 2021,
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,677,821 shares.
The largest 10 holders included
Alphabet Inc., WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, Casdin Capital, LLC, Redmile Group, LLC, BAKER BROS. ADVISORS LP, JANUS HENDERSON GROUP PLC, Rock Springs Capital Management LP, JPMORGAN CHASE & CO, and RA CAPITAL MANAGEMENT, L.P..
This page lists
69
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.